Latest Leadership News

GQG Partners Inc. reported a 6.3% increase in net revenue and a 7.3% rise in net profit for 2025, alongside a strategic US ETF launch and a new dividend declaration.

Cochlear Limited reported a modest 1% rise in HY26 sales revenue to $1.176 billion, but underlying net profit fell 9% amid slower-than-expected contract renewals for its new Nucleus Nexa implant system. The company anticipates a stronger second half and maintains full-year guidance at the lower end of its forecast.

Assetora Limited is set to be delisted from the ASX after a two-year suspension, with the company exploring a fresh listing on the National Stock Exchange of Australia to better suit its evolving business model.

Podium Minerals has disclosed the initial securities interests of its newly appointed directors, highlighting a significant allocation of performance rights to Gary Humphries while Neal Froneman holds none.

Savana Asset Management highlights the US as the leading global equity market, driven by robust economic growth, AI investment surges, and investor-friendly policies. Their insights reveal why Australian investors might look across the Pacific for growth opportunities.

Paladin Energy reported a 16% increase in uranium production and a significant rise in sales volumes for the December 2025 quarter, alongside a successful equity raise and debt restructuring that enhance its financial flexibility.

Pro Medicus has reported its strongest half-year performance yet, with revenue and profits surging alongside a wave of new multi-million dollar contracts and strategic AI investments. The healthcare IT leader is expanding its global footprint and cloud capabilities, setting the stage for sustained growth.

Aeris Resources has announced a strategic all-scrip acquisition of Peel Mining, consolidating key copper assets in New South Wales and aiming to extend the Tritton mine life beyond a decade. Peel shareholders will also retain exposure to precious metals exploration through a demerger into a new ASX-listed entity.

Elixinol Wellness reported a 9.5% revenue increase in Q4 FY25 alongside a 30% reduction in operating costs, setting a clear path to profitability under fresh executive leadership.

BlinkLab has expanded its pivotal FDA 510(k) autism diagnostic trial to nine top U.S. sites, adding Drexel University ahead of the Q1 2026 study start. This move follows a successful pilot study that exceeded FDA benchmarks, positioning BlinkLab Dx 1 for regulatory clearance.

Paladin Energy reported a strong half-year performance with uranium sales revenue climbing to US$138.3 million, driven by ramp-up at its Namibian mine and significant progress on Canadian development projects.

ASX Limited reported robust half-year results with an 11.2% rise in operating revenue and a steady net profit, while advancing its technology upgrade and responding to regulatory scrutiny.